Cargando…

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients

Secondary hyperparathyroidism (SHPT) is common in end-stage renal disease (ESRD) patients, and it can suppress erythropoiesis. We aimed to investigate the relationship between the consumption of erythropoiesis-stimulating agents (ESAs) and parathyroidectomy (PTX) in ESRD patients with SHPT and to de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yu-Ting, Tu, Chi-Wen, Kam, Kam-Hong, Ma, Tsung-Liang, Kuo, Chin-Ho, Lee, Ming-Yang, Hsiao, Chih-Yen, Chan, Michael W. Y., Hung, Peir-Haur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499136/ https://www.ncbi.nlm.nih.gov/pubmed/36142295 http://dx.doi.org/10.3390/ijms231810391

Ejemplares similares

Parathyroidectomy Is Associated with Reduced Mortality in Hemodialysis Patients with Secondary Hyperparathyroidism
por: Ma, Tsung-Liang, et al.
Publicado: (2015)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Older Age and High Serum Ferritin Levels Associated With the Risk of Chronic Cytopenia in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2020)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Relationship between Fibroblast Growth Factor 23 and Biochemical and Bone Histomorphometric Alterations in a Chronic Kidney Disease Rat Model Undergoing Parathyroidectomy
por: Liao, Hung-Wei, et al.
Publicado: (2015)

Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan
por: Hung, Peir‐Haur, et al.
Publicado: (2021)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Responsiveness to an erythropoiesis-stimulating agent is correlated with body composition in patients undergoing chronic hemodialysis
por: Lee, Hyang Yun, et al.
Publicado: (2022)

Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study
por: Hung, Peir-Haur, et al.
Publicado: (2019)

Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
por: Won, Hye Sung, et al.
Publicado: (2014)

Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
por: Koike, Kiyomi, et al.
Publicado: (2016)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
por: Nguyen, Timothy V., et al.
Publicado: (2011)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

Risk factors for uroseptic shock in hospitalized patients aged over 80 years with urinary tract infection
por: Hsiao, Chih-Yen, et al.
Publicado: (2020)

Glycated Hemoglobin < 6.5% Is Associated With Uroseptic Shock in Diabetic Patients With Urinary Tract Infection
por: Lee, Yi-Chien, et al.
Publicado: (2020)

Close correlation between the ankle-brachial index and symptoms of depression in hemodialysis patients
por: Jong, Ing-Chin, et al.
Publicado: (2017)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients
por: Brier, Michael E., et al.
Publicado: (2020)

Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2020)

Comparison of Patient Survival According to Erythropoiesis-Stimulating Agent Type of Treatment in Maintenance Hemodialysis Patients
por: Kang, Seok Hui, et al.
Publicado: (2023)

Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents
por: van der Weerd, Neelke C., et al.
Publicado: (2012)

The Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with Aceruloplasminemia
por: Nagata, Soichiro, et al.
Publicado: (2017)

Abdominal Obesity is Associated with Peripheral Artery Disease in Hemodialysis Patients
por: Hung, Peir-Haur, et al.
Publicado: (2013)

Urolithiasis Is a Risk Factor for Uroseptic Shock and Acute Kidney Injury in Patients With Urinary Tract Infection
por: Hsiao, Chih-Yen, et al.
Publicado: (2019)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
por: Bernieh, Bassam, et al.
Publicado: (2014)

Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients
por: Rivara, Matthew B., et al.
Publicado: (2015)

Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
por: Saglimbene, Valeria, et al.
Publicado: (2017)

Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis
por: Kobayashi, Shizuka, et al.
Publicado: (2022)

Investigating the relationship between erythropoiesis-stimulating agents and mortality in hemodialysis patients: A systematic review and meta-analysis
por: Karimi, Zahra, et al.
Publicado: (2023)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Risk Factors for Development of Acute Kidney Injury in Patients with Urinary Tract Infection
por: Hsiao, Chih-Yen, et al.
Publicado: (2015)

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
por: Gupta, Ajay, et al.
Publicado: (2015)

Association of the erythropoiesis-stimulating agent resistance index and the geriatric nutritional risk index with cardiovascular mortality in maintenance hemodialysis patients
por: Yajima, Takahiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cdv801d6a80tp500poi09mctv7